Abstract | BACKGROUND: METHODS: After the HUVECs were exposed to different concentrations of bevacizumab stimulated with VEGF (10 ng/ml) for 2, 6, and 24 hours, cellular-activity-like proliferation, migration and tube formation were assessed. Subconjunctival injection of bevacizumab (2.5 mg/0.1 ml) was performed after corneal chemical burn injury. Then the cornea was evaluated by biomicroscopy, fluorescein angiography, and light microscopy. RESULTS: The inhibitory effects of bevacizumab on VEGF-induced HUVECs proliferation showed a dose-dependent response for 2 and 6 hours, but all groups were effectively inhibited regardless of the concentration of bevacizumab for 24 hours. The inhibitory effects of bevacizumab on the migration of VEGF-induced HUVECs showed a time- and dose-dependent response. The inhibitory effects of bevacizumab on VEGF-induced HUVECs tube formation showed a dose-dependent response only for 24 hours. On days 3 and 8 after the subconjunctival injection, bevacizumab-treated eyes showed less neovascular growth than BSS-treated eyes in biomicroscopic, fluorescein angiographic, and light microscopic findings in vivo. CONCLUSIONS:
|
Authors | Young Sang Han, Ji Eun Lee, Ji Won Jung, Jong Soo Lee |
Journal | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
(Graefes Arch Clin Exp Ophthalmol)
Vol. 247
Issue 4
Pg. 541-8
(Apr 2009)
ISSN: 1435-702X [Electronic] Germany |
PMID | 18953554
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Cell Movement
(drug effects)
- Cell Proliferation
(drug effects)
- Cells, Cultured
- Corneal Neovascularization
(drug therapy, pathology)
- Dose-Response Relationship, Drug
- Endothelium, Vascular
(drug effects, metabolism)
- Fluorescein Angiography
- Humans
- Injections
- Neovascularization, Pathologic
(chemically induced, drug therapy, metabolism)
- Rabbits
- Umbilical Veins
(cytology)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, toxicity)
|